Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 years or older
- People with a single tumor in one breast (not spread to multiple areas), confirmed by ultrasound, MRI, or mammogram — and the tumor must be visible on ultrasound
- People whose breast cancer has been confirmed as invasive ductal carcinoma (a specific type of breast cancer) through a core needle biopsy
- People whose cancer is classified as grade 1 or 2, is hormone receptor-positive (ER/PR-positive), and HER2-negative
- People whose cancer is at an early stage (TNM stage IA), with a tumor no larger than 2 cm and no signs of cancer spread to the lymph nodes under the arm
- People who have given written agreement to take part in the trial and to be randomly assigned to a treatment group
Who may not be able to join:
- People whose imaging or pathology suggests a widespread component of cancer within the milk ducts (confirm with trial site)
- People whose cancer has grown into the nearby skin or muscle
- People who have already received any cancer treatment for this diagnosis, including chemotherapy, hormone therapy, targeted therapy, or immunotherapy
- People who are unwilling to undergo breast-conserving surgery
- People who are pregnant or breastfeeding
- People who have previously had radiotherapy to the affected breast, or who have other medical reasons they cannot receive radiotherapy
- People who have another cancer that is not being treated, or who have a serious ongoing illness
- People with a known allergy or medical reason that makes cryotherapy (a freezing treatment) unsuitable — for example, a condition called cryoglobulinemia or having an implanted electronic device
- People who are unlikely to attend follow-up appointments or who are unwilling to receive additional recommended treatments after the main treatment
- People with neurological disorders, cognitive impairment, or critical illness
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: shu wang, doctor, Peking University People's Hospital
Phone: 86+13671287670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ipsilateral Breast Tumor Recurrence Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.